Intersect ENT to Acquire Fiagon AG Medical Technologie

Intersect ENT (Nasdaq: XENT), a $109.1m developer of sinus implants and other ENT-focused products is acquiring Germany-based Fiagon, a developer of proprietary, electromagnetic-based ENT surgical navigation systems for $71.2m.  Fiagon’s instruments, produced in Germany, are tip-tracked, enabling surgeons to monitor the full range of instruments deployed during a functional endoscopic sinus surgery procedure, and they also uniquely do not require calibration.  In August 2020, Fiagon also received FDA 510(k) clearance for a navigable sinuplasty balloon.  The acquisition will expand Intersect’s product portfolio while also extending its footprint in U.S. and European ENT physicians’ offices.

Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Medical Device, ENT